Page 48 of 56: studies 471 to 480 of 555, newest first. Back to the microdosing overview
July 7, 2023 Neil Carrier, Lisa L. Gezon
This chapter focuses on drugs in spiritual and religions contexts, considering their role in altered states of consciousness, divination and healing. The first part of the chapter presents the sub-discipline of ethnobotany and its contribution to anthropological ideas about hallucinogenic plant substances and their wider connection of drugs to shamanism and the spirit world. It also discusses...
Neuropharmacology July 1, 2023 Joanna Dabrowska 6 citations
Available pharmacotherapies for anxiety disorders and post-traumatic stress-disorder (PTSD) have limited efficacy, but no new anxiolytic drug has been approved for treatment since the 1980s. In this issue of Neuropharmacology on "Fear, anxiety and PTSD: from cellular mechanisms to translational approaches", we review the currently recommended pharmacotherapy for PTSD and discuss promising...
Journal of Psychopharmacology July 1, 2023 Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji et al. 29 citations
Background: Research on psilocybin has become increasingly popular during the current psychedelic renaissance, which began in the early 1990s. Psilocybin’s effects on mental health are promising and there are ongoing efforts to investigate its clinical implementation and its effects on cognition. Aims: The purpose of this study is to report trends in publications, methods, and findings from...
Frontiers in Psychiatry June 29, 2023 Winston de la Haye, Geoffrey Walcott, Jordan Eaton et al. 6 citations
The efficacy of psilocybin and other psychedelics as modes of treatment have been demonstrated through clinical trials and other studies in the management of a number of mental illnesses, including some treatment resistant cases. In Psychedelic Assisted Psychotherapy (PAP), psychedelics catalyze or enhance the experience fostered by psychotherapeutic methods. Psychohistoriographic Brief...
June 9, 2023 Mika Turkia 3 citations preprint
This article presents the case of a young woman in her mid-twenties with a history of depression since childhood. She lived with a mother who failed to take care of her. The patient cared for the emotional needs of the mother instead of the mother caring for the daughter's needs. Her father was mostly absent. Already around the age of thirteen, the patient was severely depressed and was...
The Brown University Psychopharmacology Update May 28, 2023
expected the microdosing to change how they felt on measures of 18 affective states: angry, anxious, calm, cognitive functioning, craving, creative, connected, energy, focused, guilty, happy, meditative, motivated, open, sad, self-efficacy, stressed, and well. They were asked at the final visit to report whether microdosing actually did result in change in these states. Data on adverse events...
Salud Ciencia y Tecnología - Serie de Conferencias April 24, 2023 Nicolás Valente, Luis E. Acosta, Nadia Piazza et al.
In a context of popularization and boom of the use and research of psychedelic therapies worldwide, the therapeutic use of psilocibious fungi has gained massiveness. Its two main modalities, macrodosis (occasional use of sufficient doses to produce deep perceptual, physiological and psychological effects) and microdosis (use of dose low enough to allow the development of the person in daily...
AJOB Neuroscience April 3, 2023 Kai Rudolph
Beauchamp, T. L., and J. F. Childress. 2019. Principles of biomedical ethics. Oxford: Oxford University Press. Boyle, J. 2004. Medical ethics and double effect: the case of terminal sedation. Theoretical Medicine and Bioethics 25 (1):51–60. doi:10.1023/b:meta.0000025096.25317.22. Creutzfeldt, C. J., B. M. Kluger, and R. G. Holloway. 2019. Neuropalliative care: A guide to improving the lives of...
March 10, 2023 Mika Turkia 1 citation preprint
Ayahuasca is a plant-based brew of indigenous Amazonian origin. It has psychedelic, anti-inflammatory, neuroprotective, cytotoxic, and anti-parasitic effects, which are primarily due to monoamine oxidase inhibitors (MAOIs) and N,N-dimethyltryptamine (DMT). This article describes the case of a woman in her late thirties with complex trauma due to severe, years-long sexual abuse in early...
European Psychiatry March 1, 2023 J. Ramírez González, I. Fernández Márquez, Serafín González et al.
Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potential of hallucinogens were blocked due to their misuse in the young population. At present, psilocybin is re-emerging as the center of attention due to its possible therapeutic potential in different psychiatric pathologies such as depression, anxiety...